Global Growth Fuels Boehringer Ingelheim's Mexico Bet

Boehringer Ingelheim reported 16.2% net sales growth to €15.8 billion in 1H26, driven by US demand for JARDIANCE and new pulmonary fibrosis and oncology launches. The results coincide with a 22% increase in the company's Mexico clinical research investment for 2026, part of a broader multinational pharmaceutical push, including Pfizer, Novartis, and Roche, into Mexico's expanding clinical trial infrastructure. This trend affects Mexico's pharmaceutical manufacturing, healthcare regulatory, and clinical research sectors under the federal Plan México strategy.  

Boehringer Ingelheim closed the first half of 2026 with group net sales of €15.8 billion (US$17.8 billion), a 16.2% increase driven by strong US demand for its cardio-renal-metabolic treatment JARDIANCE and a series of new product launches. Human Pharma sales grew 20.1% to €13.1 billion, while Animal Health contributed €2.6 billion, according to the company's half-year results.

Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim, links the performance to newly launched therapies for pulmonary fibrosis and HER2-mutated lung cancer, which gained rapid traction in markets with agile regulatory pathways. "The boundaries of what is possible are continuously expanding," says Deshpande, pointing to innovation-friendly regulatory environments as a key factor behind faster patient access to new treatments.

The 1H26 results reflect a pharmaceutical sector increasingly channeling growth capital toward markets that combine large patient populations with expanding research infrastructure, a dynamic playing out prominently in Mexico. Boehringer Ingelheim is set to increase its clinical research investment in Mexico by 22% in 2026, reaching nearly MX$200 million (US$11.6 million), as part of a broader strategy to position the country as a regional hub for scientific innovation.  

The company plans to run 23 clinical studies across 177 research institutions nationwide this year, involving approximately 1,400 patients and targeting chronic conditions including heart failure, respiratory disease, and chronic kidney disease, the same conditions that anchor its global Human Pharma growth.

Established treatments for chronic kidney disease, type 2 diabetes, and heart failure remained Boehringer Ingelheim's primary growth engine globally, contributing €5.7 billion in net sales during the first half. The company attributes the gains to a growing patient base and changes in the US pricing and reimbursement environment that boosted sales volumes. Excluding this volume effect, Human Pharma's six-month growth would have tracked the broader pharmaceutical market, the company notes.

Beyond established products, Boehringer Ingelheim reported solid uptake of its recent pulmonary fibrosis and oncology launches, particularly in the United States, China, and Japan, where faster regulatory processes and stronger innovation incentives supported early adoption. Its pulmonary fibrosis treatment has already secured approvals in the United States, China, Japan, Thailand, the United Arab Emirates, the United Kingdom, and Brazil, and now awaits a decision from the European Medicines Agency. With launches in the United States, China, and Japan, the company also marked its return to oncology after a decade-long absence, with European availability of its cancer treatment anticipated from 2028 pending Phase III results.

Research and development activity remained active during the period. Boehringer Ingelheim initiated three Phase III oncology trials and advanced an experimental cancer immunotherapy and an investigational kidney disease treatment, while five new compounds entered clinical trials. The company's Human Pharma R&D pipeline now spans approximately 80 projects. In metabolic health, positive Phase III data addressing obesity and metabolic liver disease, together with progress on a next-generation triple agonist, reinforce Boehringer Ingelheim's ambition to build a broader obesity and metabolic health portfolio.

Mexico's growing weight in that global research effort mirrors a wider trend among multinational pharmaceutical companies. The federal government has received commitments exceeding MX$21 billion (US$1.1 billion) in new pharmaceutical and healthcare investment as companies including Pfizer, Novartis, and Roche expand clinical research operations in the country, a shift authorities link to Plan México, the federal strategy to strengthen domestic healthcare manufacturing and research capacity.

Looking ahead, Boehringer Ingelheim expects continued adoption of its recent launches, upcoming pipeline milestones, and sustained innovation investment to support performance through the remainder of 2026 and beyond. Mexico's expanding clinical trial footprint, backed by institutions such as the Mexican Social Security Institute, the National Cancer Institute, and the National Institute of Respiratory Diseases, positions the country to capture a growing share of that investment as global demand for Boehringer Ingelheim's cardio-metabolic and oncology treatments continues to rise.